BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-salama ZT, Syed YY, Scott LJ. Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs 2019;79:665-74. [DOI: 10.1007/s40265-019-01116-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Xu Q, Hu H, Mo Z, Chen T, He Q, Xu Z. A multifunctional nanotheranostic agent based on Lenvatinib for multimodal synergistic hepatocellular carcinoma therapy with remarkably enhanced efficacy. J Colloid Interface Sci 2023;638:375-91. [PMID: 36746055 DOI: 10.1016/j.jcis.2023.01.144] [Reference Citation Analysis]
2 Dlamini Z, Khanyile R, Molefi T, Damane BP, Bates DO, Hull R. Genomic Interplay between Neoneurogenesis and Neoangiogenesis in Carcinogenesis: Therapeutic Interventions. Cancers 2023;15:1805. [DOI: 10.3390/cancers15061805] [Reference Citation Analysis]
3 Luo YZ, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(3): 405-424 [DOI: 10.4251/wjgo.v15.i3.405] [Reference Citation Analysis]
4 Farasati Far B, Rabie D, Hemati P, Fooladpanjeh P, Faal Hamedanchi N, Broomand Lomer N, Karimi Rouzbahani A, Naimi-jamal MR. Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers 2023;3:121-160. [DOI: 10.3390/livers3010011] [Reference Citation Analysis]
5 Huang P, Wang L, Wang Y, Tsai M, Lin T, Liao C, Yeh C, Lin K. Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer. Cells 2023;12:869. [DOI: 10.3390/cells12060869] [Reference Citation Analysis]
6 Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, Chen X, Zhang B, Liang H, Liu D, Feng Y, Wang Y, Li Y, Liu B, Huang W, Xia L. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol 2023:S0168-8278(23)00172-1. [PMID: 36907560 DOI: 10.1016/j.jhep.2023.02.036] [Reference Citation Analysis]
7 Yuanren G, Yin L, Liu R, Cui Y. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1054072] [Reference Citation Analysis]
8 Xiu Z, Zhu Y, Li S, Li Y, Yang X, Li Y, Song G, Jin N, Fang J, Han J, Li Y, Li X. Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway. Journal of Functional Foods 2023;102:105441. [DOI: 10.1016/j.jff.2023.105441] [Reference Citation Analysis]
9 Li M, Zhang A, Qi X, Yu R, Li J. A novel inhibitor of PGK1 suppresses the aerobic glycolysis and proliferation of hepatocellular carcinoma. Biomed Pharmacother 2023;158:114115. [PMID: 36516697 DOI: 10.1016/j.biopha.2022.114115] [Reference Citation Analysis]
10 Iguchi K, Sada R, Matsumoto S, Kimura H, Zen Y, Akita M, Gon H, Fukumoto T, Kikuchi A. DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. Cancer Sci 2023. [PMID: 36718957 DOI: 10.1111/cas.15743] [Reference Citation Analysis]
11 Wang X, Qian S, Wang S, Jia S, Zheng N, Yao Q, Gao J. Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro. PeerJ 2023;11:e14610. [PMID: 36718449 DOI: 10.7717/peerj.14610] [Reference Citation Analysis]
12 Zhang X, Dong M, Zheng G, Zhu J, An B, Zhou Z, Bi Y, Sun M, Zhang C, Lian J, Tang S, Wang X, Liu W. Inhibition of proliferation and migration of hepatocellular carcinoma by knockdown of KIF3A via NF-κB signal pathway.. [DOI: 10.21203/rs.3.rs-2421333/v1] [Reference Citation Analysis]
13 Ma J, Bo Z, Zhao Z, Yang J, Yang Y, Li H, Yang Y, Wang J, Su Q, Wang J, Chen K, Yu Z, Wang Y, Chen G. Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765583 DOI: 10.3390/cancers15030625] [Reference Citation Analysis]
14 Chaitanya VK, Jalapathi P, Chandar MR, Vishnu T, Veerabhadraiah M, Raghavender M. Novel hybrid molecules based on triazole-quinoline as potential anticancer agents: screening on MCF-7 cell line, docking studies, and pharmacokinetics evaluation. J IRAN CHEM SOC 2023. [DOI: 10.1007/s13738-022-02737-y] [Reference Citation Analysis]
15 Krstulović L, Leventić M, Rastija V, Starčević K, Jirouš M, Janić I, Karnaš M, Lasić K, Bajić M, Glavaš-Obrovac L. Novel 7-Chloro-4-aminoquinoline-benzimidazole Hybrids as Inhibitors of Cancer Cells Growth: Synthesis, Antiproliferative Activity, in Silico ADME Predictions, and Docking. Molecules 2023;28. [PMID: 36677600 DOI: 10.3390/molecules28020540] [Reference Citation Analysis]
16 Chen X, Li J, Huang Y, Liang C. Drug Resistance in Hepatocellular Carcinoma. Interdisciplinary Cancer Research 2023. [DOI: 10.1007/16833_2022_110] [Reference Citation Analysis]
17 Butt NU, Baytas SN. Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future. Curr Pharm Des 2023;29:2-14. [PMID: 36529919 DOI: 10.2174/1381612829666221216114350] [Reference Citation Analysis]
18 Laneri F, Licciardello N, Suzuki Y, Graziano ACE, Sodano F, Fraix A, Sortino S. A Supramolecular Nanoassembly of Lenvatinib and a Green Light-Activatable NO Releaser for Combined Chemo-Phototherapy. Pharmaceutics 2022;15. [PMID: 36678725 DOI: 10.3390/pharmaceutics15010096] [Reference Citation Analysis]
19 Wang J, Wu R, Sun JY, Lei F, Tan H, Lu X. An overview: Management of patients with advanced hepatocellular carcinoma. Biosci Trends 2022;16:405-25. [PMID: 36476621 DOI: 10.5582/bst.2022.01109] [Reference Citation Analysis]
20 Luo J, Gao B, Lin Z, Fan H, Ma W, Yu D, Yang Q, Tian J, Yang X, Li B. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. Front Oncol 2022;12:1010726. [PMID: 36620586 DOI: 10.3389/fonc.2022.1010726] [Reference Citation Analysis]
21 Shen Z, Qiu B, Li L, Yang B, Li G. Targeted therapy of RET fusion-positive non-small cell lung cancer. Front Oncol 2022;12:1033484. [PMID: 36582799 DOI: 10.3389/fonc.2022.1033484] [Reference Citation Analysis]
22 Giammona G, Drago SE, Calabrese G, Varvarà P, Rizzo MG, Mauro N, Nicotra G, Conoci S, Pitarresi G. Galactosylated Polymer/Gold Nanorods Nanocomposites for Sustained and Pulsed Chemo-Photothermal Treatments of Hepatocarcinoma. Pharmaceutics 2022;14. [PMID: 36432694 DOI: 10.3390/pharmaceutics14112503] [Reference Citation Analysis]
23 Gautam AK, Kumar P, Maity B, Routholla G, Ghosh B, Chidambaram K, Begum MY, Al Fatease A, Rajinikanth P, Singh S, Saha S, M. R. V. Synthesis and appraisal of dalbergin-loaded PLGA nanoparticles modified with galactose against hepatocellular carcinoma: In-vitro, pharmacokinetic, and in-silico studies. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1021867] [Reference Citation Analysis]
24 Hu B, Zou T, Qin W, Shen X, Su Y, Li J, Chen Y, Zhang Z, Sun H, Zheng Y, Wang CQ, Wang Z, Li TE, Wang S, Zhu L, Wang X, Fu Y, Ren X, Dong Q, Qin LX. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Res 2022;82:3845-57. [PMID: 36066408 DOI: 10.1158/0008-5472.CAN-21-4140] [Reference Citation Analysis]
25 Zhang J, Ren Z, Zheng D, Song Z, Lin J, Luo Y, Zou X, Pan Y, Qi N, Li A, Liu X. AHSA1 Promotes Proliferation and EMT by Regulating ERK/CALD1 Axis in Hepatocellular Carcinoma. Cancers 2022;14:4600. [DOI: 10.3390/cancers14194600] [Reference Citation Analysis]
26 Xu Y, Fu S, Shang K, Zeng J, Mao Y. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. Front Oncol 2022;12:958869. [DOI: 10.3389/fonc.2022.958869] [Reference Citation Analysis]
27 Wang X, Qiu Z, Dong W, Yang Z, Wang J, Xu H, Sun T, Huang Z, Jin J. S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression. Cell Death Dis 2022;13:768. [PMID: 36068200 DOI: 10.1038/s41419-022-05210-z] [Reference Citation Analysis]
28 Prasoppokakorn T, Thanapirom K, Treeprasertsuk S. Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma. Case Reports in Hepatology 2022;2022:1-6. [DOI: 10.1155/2022/5101856] [Reference Citation Analysis]
29 Sun Y, Yue L, Xu P, Hu W. An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors. Front Oncol 2022;12:927587. [DOI: 10.3389/fonc.2022.927587] [Reference Citation Analysis]
30 Chen Y, Qiu X, Wu D, Lu X, Li G, Tang Y, Jia C, Xiong Z, Wang T. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. Genes 2022;13:1535. [DOI: 10.3390/genes13091535] [Reference Citation Analysis]
31 Sun Q, Wang Y, Ji H, Sun X, Xie S, Chen L, Li S, Zeng W, Chen R, Tang Q, Zuo J, Hou L, Hosaka K, Lu Y, Liu Y, Ye Y, Yang Y. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma. Cell Death Dis 2022;13:724. [PMID: 35985991 DOI: 10.1038/s41419-022-05171-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cai G, Zhu J, Ning D, Li G, Zhang Y, Xiong Y, Liang J, Yu C, Chen X, Liang H, Ding Z. A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses. Front Immunol 2022;13:997316. [DOI: 10.3389/fimmu.2022.997316] [Reference Citation Analysis]
33 Xi W, Zhou C, Xu F, Sun D, Wang S, Chen Y, Ji J, Ma T, Wu J, Shangguan C, Zhu Z, Zhang J. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA. J Transl Med 2022;20:365. [PMID: 35962408 DOI: 10.1186/s12967-022-03567-5] [Reference Citation Analysis]
34 Feng MY, Chan LL, Chan SL. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Curr Oncol 2022;29:5489-507. [PMID: 36005172 DOI: 10.3390/curroncol29080434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Zhu Y, Liu W, Wang Z, Wang Y, Tan C, Pan Z, Wang A, Liu J, Sun G. ARHGEF2/EDN1 pathway participates in ER stress-related drug resistance of hepatocellular carcinoma by promoting angiogenesis and malignant proliferation. Cell Death Dis 2022;13:652. [PMID: 35896520 DOI: 10.1038/s41419-022-05099-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Huang S, Ma Z, Zhou Q, Wang A, Gong Y, Li Z, Wang S, Yan Q, Wang D, Hou B, Zhang C. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma. Int J Biol Sci 2022;18:4357-71. [PMID: 35864956 DOI: 10.7150/ijbs.69969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhang M, Lai W, Zhang J, Hu B, Huang L, Chu C. Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma. Dis Markers 2022;2022:6957580. [PMID: 35845129 DOI: 10.1155/2022/6957580] [Reference Citation Analysis]
38 Xia Z, Kong F, Wang K, Zhang X. Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. Front Pharmacol 2022;13:908079. [PMID: 35754499 DOI: 10.3389/fphar.2022.908079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Zhao J, Guo J, Wang Y, Ma Q, Shi Y, Cheng F, Lu Q, Fu W, Ouyang G, Zhang J, Xu Q, Hu X. Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Front Oncol 2022;12:920287. [DOI: 10.3389/fonc.2022.920287] [Reference Citation Analysis]
40 Sajid M, Liu L, Sun C. The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front Immunol 2022;13:887186. [PMID: 35669776 DOI: 10.3389/fimmu.2022.887186] [Reference Citation Analysis]
41 Meng R, Zhang X, Zhou T, Luo M, Qiu Y. Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res 2022;:1-8. [PMID: 35579405 DOI: 10.1080/14737167.2022.2079498] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Liu P, Han B, Zhang Y, Wang X, Ahmad S. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. Computational Intelligence and Neuroscience 2022;2022:1-14. [DOI: 10.1155/2022/7102500] [Reference Citation Analysis]
43 Chen X, Ye Q, Chen Z, Lin Q, Chen W, Xie C, Wang X. Long non-coding RNA muskelin 1 antisense RNA as a potential therapeutic target in hepatocellular carcinoma treatment. Bioengineered 2022;13:12237-47. [PMID: 35579449 DOI: 10.1080/21655979.2022.2074703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Wu Y, Xu X, Liu M, Qin X, Wu Q, Ding H, Zhao Q. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis. Biochem Pharmacol 2022;:115093. [PMID: 35580648 DOI: 10.1016/j.bcp.2022.115093] [Reference Citation Analysis]
45 Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, Guo SD. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. Int J Biol Macromol 2022;202:539-57. [PMID: 35074329 DOI: 10.1016/j.ijbiomac.2022.01.113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
46 Kounis I, Lewin M, Laurent-Bellue A, Poli E, Coilly A, Duclos-Vallée JC, Guettier C, Adam R, Lerut J, Samuel D, Rosmorduc O. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? Ther Adv Med Oncol 2022;14:17588359221086909. [PMID: 35340695 DOI: 10.1177/17588359221086909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci 2022;23:3778. [PMID: 35409139 DOI: 10.3390/ijms23073778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
48 Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, Garmpis N, Lianos GD, Schizas D. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? JPM 2022;12:436. [DOI: 10.3390/jpm12030436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Zhang P, Sun H, Wen P, Wang Y, Cui Y, Wu J. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Mol Ther Nucleic Acids 2022;27:293-303. [PMID: 35024242 DOI: 10.1016/j.omtn.2021.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Qiao Q, Du Y, Xie L. Research advances of erianin: Source, production, biological activities and pharmacological properties. Pharmacological Research - Modern Chinese Medicine 2022;2:100059. [DOI: 10.1016/j.prmcm.2022.100059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Liu W, Quan B, Lu S, Tang B, Li M, Chen R, Ren Z, Yin X. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Front Oncol 2021;11:771045. [PMID: 35004289 DOI: 10.3389/fonc.2021.771045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer 2022;126:10-23. [PMID: 34400801 DOI: 10.1038/s41416-021-01453-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
53 Zhang H, Zhao J, Yang W, Li Z, Gong L, Li Y. Liver Cancer: Interdisciplinary Approach. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_96] [Reference Citation Analysis]
54 Cetin-Atalay R, Kahraman DC, Nalbat E, Rifaioglu AS, Atakan A, Donmez A, Atas H, Atalay MV, Acar AC, Doğan T. Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools. J Gastrointest Cancer 2021. [PMID: 34910274 DOI: 10.1007/s12029-021-00768-x] [Reference Citation Analysis]
55 Cui Y, Li Y, Fan L, An J, Wang X, Fu R, Dong Z. UPLC-MS/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies. J Pharm Biomed Anal 2021;206:114360. [PMID: 34508926 DOI: 10.1016/j.jpba.2021.114360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Liu J, Li Z, Zhang W, Lu H, Sun Z, Wang G, Han X. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients. Front Pharmacol 2021;12:709060. [PMID: 34733154 DOI: 10.3389/fphar.2021.709060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
57 Mou L, Tian X, Zhou B, Zhan Y, Chen J, Lu Y, Deng J, Deng Y, Wu Z, Li Q, Song Y, Zhang H, Chen J, Tian K, Ni Y, Pu Z. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Front Oncol 2021;11:752725. [PMID: 34707994 DOI: 10.3389/fonc.2021.752725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
58 Zhao W, Jiang L, Fang T, Fang F, Liu Y, Zhao Y, You Y, Zhou H, Su X, Wang J, Liu S, Chen Y, Wan J, Huang X. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation. Front Oncol 2021;11:747282. [PMID: 34676172 DOI: 10.3389/fonc.2021.747282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
59 Guo J, Zhu P, Ye Z, Wang M, Yang H, Huang S, Shu Y, Zhang W, Zhou H, Li Q. YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. Front Pharmacol 2021;12:744578. [PMID: 34658879 DOI: 10.3389/fphar.2021.744578] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
61 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Lu Y, Jin J, Du Q, Hu M, Wei Y, Wang M, Li H, Li Q. Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. Front Cell Dev Biol 2021;9:730240. [PMID: 34568339 DOI: 10.3389/fcell.2021.730240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Sun G, Rong D, Li Z, Sun G, Wu F, Li X, Cao H, Cheng Y, Tang W, Sun Y. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Front Cell Dev Biol 2021;9:694363. [PMID: 34568317 DOI: 10.3389/fcell.2021.694363] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
64 Chen J, Wang J, Xie F. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis. Medicine (Baltimore) 2021;100:e27013. [PMID: 34559096 DOI: 10.1097/MD.0000000000027013] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Charneau J, Suzuki T, Shimomura M, Fujinami N, Nakatsura T. Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. J Hepatocell Carcinoma 2021;8:1035-54. [PMID: 34513746 DOI: 10.2147/JHC.S291558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
66 Chen YY, Chen CL, Lin CC, Wang CC, Liu YW, Li WF, Chen YH. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers (Basel) 2021;13:4584. [PMID: 34572811 DOI: 10.3390/cancers13184584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
67 Hao J, Peng Q, Wang K, Yu G, Pan Y, Du X, Hu N, Zhang X, Qin Y, Li H. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway. Biomed Res Int 2021;2021:6613439. [PMID: 34337035 DOI: 10.1155/2021/6613439] [Reference Citation Analysis]
68 Caballeria-Casals A, Micó-Carnero M, Rojano-Alfonso C, Maroto-Serrat C, Casillas-Ramírez A, Álvarez-Mercado AI, Gracia-Sancho J, Peralta C. Role of FGF15 in Hepatic Surgery in the Presence of Tumorigenesis: Dr. Jekyll or Mr. Hyde? Cells 2021;10:1421. [PMID: 34200439 DOI: 10.3390/cells10061421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Damiris K, Abbad H, Pyrsopoulos N. Cellular based treatment modalities for unresectable hepatocellular carcinoma. World J Clin Oncol 2021; 12(5): 290-308 [PMID: 34131562 DOI: 10.5306/wjco.v12.i5.290] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
71 Zong J, Peng H, Qing X, Fan Z, Xu W, Du X, Shi R, Zhang Y. pH-Responsive Pluronic F127-Lenvatinib-Encapsulated Halogenated Boron-Dipyrromethene Nanoparticles for Combined Photodynamic Therapy and Chemotherapy of Liver Cancer. ACS Omega 2021;6:12331-42. [PMID: 34056385 DOI: 10.1021/acsomega.1c01346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
72 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
73 Liang X, Wu P, Yang Q, Xie Y, He C, Yin L, Yin Z, Yue G, Zou Y, Li L, Song X, Lv C, Zhang W, Jing B. An update of new small-molecule anticancer drugs approved from 2015 to 2020. Eur J Med Chem 2021;220:113473. [PMID: 33906047 DOI: 10.1016/j.ejmech.2021.113473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
74 Hu Q, Hu X, Zhang L, Zhao Y, Li L. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency. Med Oncol 2021;38:41. [PMID: 33730237 DOI: 10.1007/s12032-021-01487-w] [Reference Citation Analysis]
75 Guo Y, Xu J, Du Q, Yan Y, Geller DA. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin. Transl Oncol 2021;14:101059. [PMID: 33735820 DOI: 10.1016/j.tranon.2021.101059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
76 He W, Huang X, Berges BK, Wang Y, An N, Su R, Lu Y. Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells. Front Pharmacol 2021;12:615889. [PMID: 33716742 DOI: 10.3389/fphar.2021.615889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
77 Skubalova Z, Rex S, Sukupova M, Zahalka M, Skladal P, Pribyl J, Michalkova H, Weerasekera A, Adam V, Heger Z. Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System. Int J Nanomedicine 2021;16:1-14. [PMID: 33442247 DOI: 10.2147/IJN.S275808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Jia J, Che L, Cigliano A, Wang X, Peitta G, Tao J, Zhong S, Ribback S, Evert M, Chen X, Calvisi DF. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis. Int J Mol Sci 2020;21:E8467. [PMID: 33187130 DOI: 10.3390/ijms21228467] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
79 Li HY, Yin FF, Li XY, Jia WN, Ding J, Zhang L, Wang ZH, Hu QQ, Zuo JL, Jia HL, Wang LH, Fan CH, Gu HZ, Wu J. Novel aptasensor-based assay of sonic hedgehog ligand for detection of portal vein invasion of hepatocellular carcinoma. Biosens Bioelectron 2021;174:112738. [PMID: 33257185 DOI: 10.1016/j.bios.2020.112738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
80 Dong H, Wang M, Chang C, Sun M, Yang F, Li L, Feng M, Zhang L, Li Q, Zhu Y, Qiao Y, Xie T, Chen J. Erianin inhibits the oncogenic properties of hepatocellular carcinoma via inducing DNA damage and aberrant mitosis. Biochem Pharmacol 2020;182:114266. [PMID: 33035506 DOI: 10.1016/j.bcp.2020.114266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
81 Bai W, Ji J, Huang Q, Wei W. Synthesis and evaluation of new thiourea derivatives as antitumor and antiangiogenic agents. Tetrahedron Letters 2020;61:152366. [DOI: 10.1016/j.tetlet.2020.152366] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
82 Cacicedo ML, Medina-Montano C, Kaps L, Kappel C, Gehring S, Bros M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells 2020;9:E1985. [PMID: 32872352 DOI: 10.3390/cells9091985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Scott JD, Liu S, Klatt KC, Sun Z, Guo Q, Grimm SL, Coarfa C, Dong B, Moore DD. Constitutive Androstane Receptor and Hepatitis B Virus X Protein Cooperatively Induce β-catenin-Activated Liver Tumors.. [DOI: 10.1101/2020.08.08.241661] [Reference Citation Analysis]
84 Yang J, Zhao Z, Hu K, Zhou C, Wang Y, Song S, Zhao J, Gong Z. Strongylocentrotus nudus lipids induce apoptosis in HepG2 cells through the induction of oxidative stress. Food Bioscience 2020;36:100621. [DOI: 10.1016/j.fbio.2020.100621] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Li KS, Zhu XD, Liu HD, Zhang SZ, Li XL, Xiao N, Liu XF, Xu B, Lei M, Zhang YY, Shi WK, Cao MQ, Xu YF, Tang ZY, Sun HC. NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. Cell Death Dis 2020;11:335. [PMID: 32382041 DOI: 10.1038/s41419-020-2549-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
86 Ding Z, Ericksen RE, Escande-Beillard N, Lee QY, Loh A, Denil S, Steckel M, Haegebarth A, Wai Ho TS, Chow P, Toh HC, Reversade B, Gruenewald S, Han W. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J Hepatol 2020;72:725-35. [PMID: 31726117 DOI: 10.1016/j.jhep.2019.10.026] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
87 Fu R, Jiang S, Li J, Chen H, Zhang X. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. Med Oncol 2020;37:24. [PMID: 32166604 DOI: 10.1007/s12032-020-01350-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 11.7] [Reference Citation Analysis]
88 Ma XL, Hu B, Tang WG, Xie SH, Ren N, Guo L, Lu RQ. CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol 2020;13:11. [PMID: 32024555 DOI: 10.1186/s13045-020-0845-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
89 Heslop KA, Rovini A, Hunt EG, Fang D, Morris ME, Christie CF, Gooz MB, DeHart DN, Dang Y, Lemasters JJ, Maldonado EN. JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cells. Biochem Pharmacol 2020;171:113728. [PMID: 31759978 DOI: 10.1016/j.bcp.2019.113728] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]